The target user group is rare disease researchers. A series of problems plague this space:

There are over 7,000 different types of rare diseases, affecting an estimated 25-30 million people in the United States alone.[1][5]
95% of rare diseases lack an FDA-approved treatment.[1] This is largely due to the high costs and difficulties in conducting clinical trials with limited patient pools.
On average, it takes 4.8 years for a rare disease patient to receive an accurate diagnosis.[1] The diagnostic odyssey is long and arduous, delaying potential treatment.
Only 1 in 2 rare diseases have a foundation or research support group behind them, leaving many without advocacy or funding for research.[1]
3 out of 10 children with a rare disease will not live to see their 5th birthday.[1] Many rare diseases are serious, life-threatening conditions lacking effective therapies.
Studying rare diseases is challenging due to small data and sample sizes. For instance, one study on alkaptonuria, a rare metabolic disorder, had a cohort of just 125 patients - the largest of its kind.[3]
Pharmaceutical companies have historically lacked incentives to invest in developing treatments for rare diseases with small market potential. The Orphan Drug Act of 1983 aimed to address this by providing financial incentives.[3]
